why choose us

300×250 Ad Slot

Research Article: Serum circRNA_ is a Prognostic Biomarker in Acute Myeloid Leukemia

Date Published: 2023-10-16

Abstract:
Blood cancer, AML, develops from the aberrant proliferation and differentiation of myeloid cells in the bone marrow. Due to the wide range of genetic and molecular abnormalities that cause it, patients with the same diagnosis will have vastly different clinical outcomes and responses to therapy. In AML, immature myeloid cells accumulate in the bone marrow and peripheral blood, causing symptoms including anemia, infections, and bleeding. Treating older or ineligible patients who cannot receive intensive chemotherapy can be particularly challenging,, as can treating relapsed or refractory AML patients.– Despite the significant progress made in AML treatment, the -year OS rate for patients with AML remains poor, ranging from % to %., The diagnosis of AML usually involves bone marrow biopsy and genetic testing to determine the subtype and risk classification of the disease, which guides treatment decisions. Therefore, there is a critical need to find new and reliable prognostic biomarkers to help stratify the risk of AML patients and select optimal therapeutic strategies to improve clinical outcomes.,

Introduction:
Blood cancer, AML, develops from the aberrant proliferation and differentiation of myeloid cells in the bone marrow. Due to the wide range of genetic and molecular abnormalities that cause it, patients with the same diagnosis will have vastly different clinical outcomes and responses to therapy. In AML, immature myeloid cells accumulate in the bone marrow and peripheral blood, causing symptoms including anemia, infections, and bleeding. Treating older or ineligible patients who cannot receive intensive…

Read more

300×250 Ad Slot